Well not far off on my Quarterly Rev estimate (my estimate a few days back $4.18m) vs $4.14m, up 9%. Cashflow was still negative ($326k), but looked like $235k was some sort of unspecified one off investment/acquisition of some asset.
Looks like shareholders will get an update at the AGM on the Medivet divestment. - Is anyone going to this? I don't think I'm going to be able to get along on the 13th, but hopefully someone from HC makes it?
Some nice additions to the Tuta business and potential there to expand offerings, given these are used in teaching the natural progression would be to roll out to hospitals.
Focus appears to be Queensland and potentially rolling sales out to SE Asia. Naturally makes sense given the lower cost of MLAs products and the proximity to a large developing market.
Overall not too bad, Would like to get the Medivet update. The Human Healthcare business is trading well enough to support the business for awhile longer yet, so fortunately there's no fire sale required.
DYOR, IMO etc....
MLA Price at posting:
5.0¢ Sentiment: Buy Disclosure: Held
